Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges
Age-related disorders of the musculoskeletal system including sarcopenia, osteoporosis and arthritis represent some of the most common chronic conditions worldwide, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. Collectively, these con...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/1/237 |
| _version_ | 1797437767700971520 |
|---|---|
| author | Thomas A. Nicholson Michael Sagmeister Susanne N. Wijesinghe Hussein Farah Rowan S. Hardy Simon W. Jones |
| author_facet | Thomas A. Nicholson Michael Sagmeister Susanne N. Wijesinghe Hussein Farah Rowan S. Hardy Simon W. Jones |
| author_sort | Thomas A. Nicholson |
| collection | DOAJ |
| description | Age-related disorders of the musculoskeletal system including sarcopenia, osteoporosis and arthritis represent some of the most common chronic conditions worldwide, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. Collectively, these conditions involve multiple tissues, including skeletal muscle, bone, articular cartilage and the synovium within the joint lining. In this review, we discuss the potential for oligonucleotide therapies to combat the unmet clinical need in musculoskeletal disorders by evaluating the successes of oligonucleotides to modify candidate pathological gene targets and cellular processes in relevant tissues and cells of the musculoskeletal system. Further, we discuss the challenges that remain for the clinical development of oligonucleotides therapies for musculoskeletal disorders and evaluate some of the current approaches to overcome these. |
| first_indexed | 2024-03-09T11:27:22Z |
| format | Article |
| id | doaj.art-3c50e07dfebf40e6ad3ecf4a810d2210 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T11:27:22Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-3c50e07dfebf40e6ad3ecf4a810d22102023-11-30T23:59:36ZengMDPI AGPharmaceutics1999-49232023-01-0115123710.3390/pharmaceutics15010237Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and ChallengesThomas A. Nicholson0Michael Sagmeister1Susanne N. Wijesinghe2Hussein Farah3Rowan S. Hardy4Simon W. Jones5MRC Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UKInstitute for Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, UKMRC Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UKMRC Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UKInstitute for Metabolism and Systems Research, University of Birmingham, Birmingham B15 2TT, UKMRC Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UKAge-related disorders of the musculoskeletal system including sarcopenia, osteoporosis and arthritis represent some of the most common chronic conditions worldwide, for which there remains a great clinical need to develop safer and more efficacious pharmacological treatments. Collectively, these conditions involve multiple tissues, including skeletal muscle, bone, articular cartilage and the synovium within the joint lining. In this review, we discuss the potential for oligonucleotide therapies to combat the unmet clinical need in musculoskeletal disorders by evaluating the successes of oligonucleotides to modify candidate pathological gene targets and cellular processes in relevant tissues and cells of the musculoskeletal system. Further, we discuss the challenges that remain for the clinical development of oligonucleotides therapies for musculoskeletal disorders and evaluate some of the current approaches to overcome these.https://www.mdpi.com/1999-4923/15/1/237skeletal musclesarcopeniaosteoarthritisosteoporosisrheumatoid arthritisoligonucleotides |
| spellingShingle | Thomas A. Nicholson Michael Sagmeister Susanne N. Wijesinghe Hussein Farah Rowan S. Hardy Simon W. Jones Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges Pharmaceutics skeletal muscle sarcopenia osteoarthritis osteoporosis rheumatoid arthritis oligonucleotides |
| title | Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges |
| title_full | Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges |
| title_fullStr | Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges |
| title_full_unstemmed | Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges |
| title_short | Oligonucleotide Therapeutics for Age-Related Musculoskeletal Disorders: Successes and Challenges |
| title_sort | oligonucleotide therapeutics for age related musculoskeletal disorders successes and challenges |
| topic | skeletal muscle sarcopenia osteoarthritis osteoporosis rheumatoid arthritis oligonucleotides |
| url | https://www.mdpi.com/1999-4923/15/1/237 |
| work_keys_str_mv | AT thomasanicholson oligonucleotidetherapeuticsforagerelatedmusculoskeletaldisorderssuccessesandchallenges AT michaelsagmeister oligonucleotidetherapeuticsforagerelatedmusculoskeletaldisorderssuccessesandchallenges AT susannenwijesinghe oligonucleotidetherapeuticsforagerelatedmusculoskeletaldisorderssuccessesandchallenges AT husseinfarah oligonucleotidetherapeuticsforagerelatedmusculoskeletaldisorderssuccessesandchallenges AT rowanshardy oligonucleotidetherapeuticsforagerelatedmusculoskeletaldisorderssuccessesandchallenges AT simonwjones oligonucleotidetherapeuticsforagerelatedmusculoskeletaldisorderssuccessesandchallenges |